enGene Holdings Secures $60 Million for Genetic Medicines
Company Announcements

enGene Holdings Secures $60 Million for Genetic Medicines

enGene Holdings ( (ENGN) ) has provided an announcement.

enGene Holdings Inc. plans a $60 million private placement of 6.7 million common shares at $8.90 each, aiming to fund the development of its genetic medicines, particularly detalimogene for bladder cancer. This financing, involving investors like Deep Track Capital and OrbiMed, is expected to close on October 29, 2024. The proceeds are anticipated to support enGene’s operations through 2027. With placement agents including Leerink Partners and Piper Sandler, the securities offered are exempt from U.S. registration, aligning with Nasdaq rules.

For a thorough assessment of ENGN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyenGene files to sell 46.98M common shares, 6.29M warrants for holders
TheFlyenGene files $300M mixed securities shelf
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App